Zevra Therapeutics, Inc. ZVRA Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?
- Zevra Therapeutics, Inc. (ZVRA) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of $233K in Q1 2026.
- How has Zevra Therapeutics, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?
- Zevra Therapeutics, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash increased by 162.6% year-over-year, from -$372K to $233K.
- What is the long-term trend for Zevra Therapeutics, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?
- Over 2 years (2022 to 2024), Zevra Therapeutics, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash has grown at a 49.2% compound annual growth rate (CAGR), from $204K to $454K.